The socio‐economic burden of H1‐antihistamine‐refractory chronic spontaneous urticaria in Germany

Matthias Augustin,Dominik Beier,Jennifer Branner,Dennis Häckl,Regina Hampel,Thomas Kramps,Hjalmar Kurzen,Hannah Lintener,Nima Melzer,Malina Müller,Petra Staubach,Uwe Schwichtenberg,Christian Termeer,Alexander Zink,Petra Nathan,Marcus Maurer
DOI: https://doi.org/10.1111/jdv.20071
2024-05-12
Journal of the European Academy of Dermatology and Venereology
Abstract:Background and Study Aim Data from the AWARE study (A Worldwide Antihistamine‐Refractory chronic urticaria patient Evaluation) illustrate a substantial disease burden in German patients with H1‐antihistamine (‐H1‐AH)‐refractory chronic spontaneous urticaria (CSU). Detrimental effects on patients' quality of life, poor disease control and impairment in the ability to work and perform other daily activities are reported. Based on these findings, this study aims to quantify the epidemiological and socio‐economic burden of H1‐AH‐refractory CSU in Germany. Methods To determine the epidemiological burden of H1‐AH‐refractory CSU, the age‐ and gender‐specific prevalence of CSU and the proportion of H1‐AH‐refractory patients in Germany anonymized data from the InGef research database have been used. In a second step, the socio‐economic burden in terms of lost numbers of hours in paid and unpaid work was calculated by extrapolating the age‐ and gender‐specific work productivity and activity impairment (WPAI) observed in AWARE to the H1‐AH‐refractory CSU population in Germany. Finally, productivity losses in paid and unpaid work were monetized using the human capital and the friction cost approach respectively. Moreover, socio‐economic burden was calculated depending on symptom control of the patients (measured by urticaria control test [UCT]). Results In Germany, over 203,000 patients (20 years or older) had H1‐AH‐refractory CSU in 2018. The avoided lost paid and unpaid work hours attributable to H1‐AH‐refractory CSU summed up to over 100 million. Overall, the socio‐economic burden of H1‐AH‐refractory CSU in monetary terms was evaluated at € 2.2 billion and the majority of this was due to unpaid work loss. Patients with poor disease control, as indicated by UCT score
dermatology
What problem does this paper attempt to address?